Ainos Seeks FDA Nod For Mid-Stage Covid-19 Study


Ainos, Inc. AIMD has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its drug candidate VELDONA, for treatment of mild symptoms related to COVID-19.

The company has developed its low-dose oral IFN-alpha formulation VELDONA® to boost the human immune response against disease and infection.

The Phase 2 trial is expected to involve a multicenter and parallel study conducted in Taiwan to evaluate the efficacy of VELDONA in subjects with mild symptoms related to COVID-19.

The enrolled subjects will receive either a daily oral dose of VELDONA or a standard of care (SoC) for 5 days and will be evaluated throughout a 28-day study period.

Chun-Hsien Tsai, Chairman of the Board, President and CEO, commented : "Patients with severe and critical COVID-19 conditions, seem to be affected by an impairment in type I IFN response (no IFN-beta and low IFN-alpha production and activity). Our Company is investigating whether impaired type I IFN could be related to persistent high blood viral loads and inflammatory responses in COVID-19 cases."

The company noted, the previous studies have demonstrated that VELDONA could inhibit respiratory virus infection, including influenza A.

Price Action : Ainos shares are trading around 1 percent down at $2.43 on Wednesday during pre-market session.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksHealth CareGeneralIND Filing
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!